Related Experiment Videos
Pharmacotherapy for diabetic retinopathy
Grant M Comer1, Thomas A Ciulla
1Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Current Opinion in Ophthalmology
|November 4, 2004
Summary
New pharmacologic strategies are being developed to combat vision loss from diabetic retinopathy (DR). Current research focuses on understanding microscopic changes to improve treatment beyond standard interventions for this complication of diabetes.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Background:
- Diabetic retinopathy (DR) is a severe complication of diabetes causing vision loss despite current treatments.
- Standard interventions include glycemic control, blood pressure management, and laser photocoagulation.
- There is a critical need for more effective pharmacologic treatments for DR.
Purpose of the Study:
- To review recent advances in understanding the microscopic changes in DR.
- To explore novel pharmacologic prevention and treatment strategies for DR.
- To evaluate emerging therapeutic targets and ongoing clinical trials.
Main Methods:
- Review of animal models and human clinical studies.
- Analysis of research on growth factor modulation (VEGF, PEDF).
- Investigation of alternative pathways like dyslipidemia, hypoxia, and sorbitol metabolism.
Main Results:
- Ongoing trials for anti-VEGF and PKC inhibitors in diabetic macular edema.
- Elevated PEDF found with active neovascularization, challenging prior assumptions.
- Mixed results for various agents; some show promise (triamcinolone acetonide, interferon alpha-2a), while others do not (losartan, vitamins C/E, atorvastatin).
Conclusions:
- Animal models have significantly advanced understanding of DR pathogenesis.
- Human clinical studies are exploring diverse therapeutic avenues.
- Further research is essential to develop superior pharmacologic treatments for DR.